Phase 3 interim results of Covaxin released April 21, 2021 Clinical efficacy at 78%; 100% efficacy against severe Covid-19 disease: Bharat Biotech Bharat Biotech has announced Phase 3 interim analysis results of Covaxin, following a second interim analysis based on 87 symptomatic cases of Covid-19. Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per centagainst mild, moderate, and severe Covid-19 disease. The efficacy against severe Covid-19 disease was 100 per cent, with an impact on reduction in hospitalisations. The efficacy against asymptomatic Covid-19 infection was 70 per cent, suggesting decreased transmission in Covaxin recipients. Safety and efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication. Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of Covaxin.